KCA
Search
- Page Path
- HOME > Search
Original Article
- General
- Reclassification of Five BRCA1/2 Variants with Unknown Significance Using Complex Functional Study
- Anikó Bozsik, János Papp, Vince Kornél Grolmusz, Attila Patócs, Edit Oláh, Henriett Butz
- Cancer Res Treat. 2022;54(4):970-984. Published online February 8, 2022
- DOI: https://doi.org/10.4143/crt.2021.1078
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
While BRCA1/2 genes are commonly investigated, variants of unknown significance (VUS) and variants with potential splice effect are still being detected and they represent a substantial challenge in genetic counseling and therapy.
Materials and Methods
Out of genetically tested 3,568 hereditary breast and ovarian cancer probands five, functionally not investigated variants with potential splice-modifying effect were subjected to functional characterization. Transcript-level analysis on peripheral blood-derived RNA of the carriers was performed to test aberrant splicing. The completeness of the aberrant splicing event was also studied, existence and extent of nonsense-mediated decay was even addressed. Clinical and phenotype data, pedigree and co-segregation analyses were also done. Locus-specific loss of heterozygosity (LOH) in tumor tissues was additionally tested.
Results
In case of the BRCA1:c.4484+4dupA and the BRCA1:c.5407-10G>A variants functional results allowed us to reclassify them from VUS into likely pathogenic category. BRCA1:c.4358-31A>C, by producing incomplete aberrant splicing, was highlighted as strong VUS, but in lack of other supporting evidence, re-categorization was not possible. The likely pathogenic assertion of previously not reported BRCA2:c.8487G>T was reinforced based on its spliceogenic property and tumor LOH, while BRCA2:c.793G>A failed to present aberrant splicing in spite of suggestive predictions, which altered its original VUS evaluation into likely benign class.
Conclusion
We presented molecular and clinical evidence for reclassification of four out of five BRCA1/2 variants. Both up- and down-classification harbour important clinical significance. Patients carrying re-classified pathogenic variants in the future will not be dropped out from medical surveillance, preventive measures, treatment and predictive family screening in relatives at risk. -
Citations
Citations to this article as recorded by
- Korean patients with hereditary cancer: a prospective multicentre cohort study protocol exploring psychosocial and health outcomes
Jun-Kyu Kim, Mi-Ae Jang, Jong Eun Park, Dongju Won, Jung-Sook Ha, Kyoung-Bo Kim, Boyoung Park, Sun-Young Kong
BMJ Open.2025; 15(2): e093905. CrossRef - Genome sequencing-based discovery of a novel deep intronic APC pathogenic variant causing exonization
Anikó Bozsik, Henriett Butz, Vince Kornél Grolmusz, Csaba Polgár, Attila Patócs, János Papp
European Journal of Human Genetics.2023; 31(7): 841. CrossRef - Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre
Henriett Butz, Anikó Bozsik, Vince Grolmusz, Erika Szőcs, János Papp, Attila Patócs
Scientific Reports.2023;[Epub] CrossRef
- Korean patients with hereditary cancer: a prospective multicentre cohort study protocol exploring psychosocial and health outcomes
- 7,898 View
- 262 Download
- 4 Web of Science
- 3 Crossref
First
Prev
